Mon. 5 Feb 2024, 8:09am ET
Benzinga
Biotech, News, General
- RT-111 achieved high bioavailability in humans -
- RT-111 was well-tolerated, with no serious adverse events -
- Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints –
- Rani has now successfully completed three Phase 1 trials using RaniPill® technology -
- Company to host conference call today at 8:30 a.m. ET / 5:30 a.m. PT –